Access the full text.
Sign up today, get DeepDyve free for 14 days.
Ying Kong, J. Seldon (2004)
Pseudo-Generic Products and Barriers to Entry in Pharmaceutical MarketsReview of Industrial Organization, 25
R. Caves, M. Whinston, M. Hurwitz (1991)
Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry, 22
M. Hurwitz, R. Caves (1988)
Persuasion or Information? Promotion and the Shares of Brand Name and Generic PharmaceuticalsThe Journal of Law and Economics, 31
R. Schmalensee (1978)
Entry Deterrence in the Ready-to-Eat Breakfast Cereal IndustryThe Bell Journal of Economics, 9
Ida Ferrara, Ying Kong (2008)
Can health insurance coverage explain the generic competition paradoxEconomics Letters, 101
D. Reiffen, Michael Ward (2005)
'Branded Generics' as a Strategy to Limit Cannibalization of Pharmaceutical MarketsHealth Economics
Nina Pavenik (2002)
Do pharmaceutical prices respond to potential patient out-of-pocket expenses?The Rand journal of economics, 33 3
R. Frank, D. Salkever (1995)
Generic Entry and the Pricing of Pharmaceuticals
H. Grabowski, J. Vernon (1992)
Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug ActThe Journal of Law and Economics, 35
S. Salant, Sheldon Switzer, R. Reynolds (1983)
Losses From Horizontal Merger: The Effects of an Exogenous Change in Industry Structure on Cournot-Nash EquilibriumQuarterly Journal of Economics, 98
M. Baye, K. Crocker, Jiandong Ju (1996)
Divisionalization, Franchising, and Divestiture Incentives in OligopolyThe American Economic Review, 86
Reiffen (2007)
?Branded Generics? as a Strategy to Limit Cannibalization of Pharmaceutical MarketsManagerial and Decision Economics, 28
Abstract Facing generic competition, brand-name drug companies sometimes launch their own generics called “authorised generics” (AGs) through a third-party entity. If that strategy works, an AG should be launched for every branded drug that comes off patent. This, however, contradicts the fact that only a small proportion of branded drugs have had AGs. To explain this puzzle, I develop a two-period model in which a brand-name drug company exploits its name brand before generic entry. The model predicts that the brand-name company launches an AG only when brand loyalty is sufficiently weak.
The Japanese Economic Review – Springer Journals
Published: Sep 1, 2018
Keywords: economics, general; microeconomics; macroeconomics/monetary economics//financial economics; econometrics; development economics; economic history
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.